The James Buchanan Brady Urological Institute
 
 
 
The Ralph T. and Esther L. Warburton Foundation and
Dr. Hugh Judge Jewett
Fellowship in Urologic Oncology
           
About the Fellowship
Program Description
Clinical Experience
Research Experience
Faculty
Living in Baltimore
Application Process
urologic oncology prostate cancer

The Ralph T. and Esther L. Warburton Foundation and Dr. Hugh Judge Jewett Fellowship in Urologic Oncology at the Brady Urological Institute provides comprehensive multidisciplinary training in all aspects of urologic cancer surgery including open, laparoscopic, and robotic-assisted techniques for disease management. It is our goal to train future leaders in academic urologic oncology with the most up-to-date clinical and research skills to make significant contributions in the field.

The Oncology Fellow will have an opportunity to work directly with faculty in the Department who perform open and minimally-invasive surgical procedures for treatment of urological malignancies. The fellowship is a two-year program that includes one year of clinical urologic oncology and one protected year of research. The fellow is appointed as Instructor in Urology with full hospital admitting, operative, and clinic privileges

**NOTE: We are accepting applications for a Fellow to begin on July 1, 2016.**


Areas of surgical training include:

  • Prostate cancer - open radical retropubic and robotic laparoscopic radical prostatectomy, transperitoneal and extraperitoneal approaches; cryoablation
  • Kidney cancer - open partial/radical nephrectomy including IVC thrombectomy; laparoscopic radical nephrectomy; robotic partial nephrectomy
  • Urothelial cancer - open and robotic radical cystectomy; orthotopic neobladder reconstruction and continent urinary reconstruction (conduit, pouch, neobladder); open, laparoscopic and robotic nephroureterectomy; partial cystectomy, TURBT
  • Testis cancer – orchiectomy; open and robotic RPLND

Areas of research training include:

  • Prostate – active surveillance, serum and urinary biomarkers, genomics, high-risk disease, adjuvant therapy, advanced imaging, neoadjuvant clinical trials, MRI-guided biopsy, intraoperative imaging, epidemiology, outcomes
  • Kidney – active surveillance, biomarkers, ablation, outcomes, targeted therapy, in vivo imaging
  • Bladder – tissue engineering, high risk disease, biomarkers

 



U.S. News and World Report Rankings Badge

 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: webmaster@urology.jhu.edu | 600 North Wolfe Street, Baltimore, Maryland 21287